API Product   :    Teriflunomide*
CEP   :    -
WCC   :    ?
Therapeutic Use    :    Immunostimulating Agents; Other CNS Drugs
Originator   :    Sanofi-Aventis
CAS No.    :    163451-81-8
Trade Name.   :    AUBAGIO
Molecular Weight   :    270.207 g/mol
Molecular Formula   :    C12H9F3N2O2
Teriflunomide affects the immune system and reduces swelling and inflammation in the nervous system. Teriflunomide is used to reduce flare-ups in people with relapsing multiple sclerosis (MS). Teriflunomide is not a cure for MS. Teriflunomide may also be used for purposes not listed in this medication guide.
Teriflunomide (trade name Aubagio, marketed by Sanofi) is the active metabolite of leflunomide.[1] Teriflunomide was investigated in the Phase III clinical trialTEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010.[2] 2-year results were positive.[3] However, the subsequent TENERE head-to-head comparison trial reported that "although permanent discontinuations [of therapy] were substantially less common among MS patients who received teriflunomide compared with interferon beta-1a, relapses were more common with teriflunomide.